US · GRI
GRI Bio, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- La Jolla, CA 92037
- Website
- gribio.com
Price · as of 2025-12-31
$2.18
Market cap 229.07K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $173.27 | +7,848.17% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $7,225,109.00 | ||||
| 2021 | $9,200,318.00 | $3,763,621.70 | |||
| 2022 | $552,279.00 | ||||
| 2023 | $5,433.06 | ||||
| 2024 | $183.65 | $14,337.06 | $0.00 | ||
| 2025 | $2.54 | $173.27 |
AI valuation
Our deep-learning model estimates GRI Bio, Inc.'s (GRI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $173.27
- Current price
- $2.18
- AI upside
- +7,848.17%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GRI | GRI Bio, Inc. | $2.18 | 229.07K | +7,848% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| ABP | Abpro Corporation | $0.27 | 538.98K | +18,772% | +8,137% | — | — | -0.66 | -0.31 | 26.19 | -0.85 | — | -0.30 | 100.00% | -5421.31% | -3951.91% | 14.30% | 20.14% | -180.44% | -0.21 | -25.64 | 0.19 | 0.16 | -0.08 | -3840.00% | 5000.00% | 2121.00% | -188.40% | -0.46 | 18.33% | 0.00% | 0.00% | 35.32% | -0.53 | -0.58 | 28.80 | -45.79 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GNPX | Genprex, Inc. | $2.00 | 3.26M | — | — | — | — | -0.06 | 0.84 | — | 0.01 | — | 0.84 | 0.00% | — | — | -467.24% | -6073.62% | -285.38% | 0.00 | — | 0.83 | 0.64 | 0.08 | -7633.00% | — | -3088.00% | -1259.09% | -6.85 | -4919.06% | 20346.13% | -1312.70% | 20346.13% | 0.01 | 0.01 | — | -69.29 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| JAGX | Jaguar Health, Inc. | $0.89 | 1.93M | +7,724% | +550% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| SXTP | 60 Degrees Pharmaceutical… | $3.11 | 2.51M | +12,794% | +37,941,033% | — | — | -0.09 | 0.18 | 1.17 | 0.32 | 0.00 | 0.18 | 36.67% | -1598.97% | -1308.01% | -178.66% | -524.57% | -117.49% | 0.04 | -1227.87 | 3.25 | 2.34 | 0.19 | 185263.00% | 13961.00% | 2512.00% | -822.00% | -3.41 | -314.75% | 0.00% | 0.00% | 0.00% | 0.26 | 0.43 | -4.15 | -14.30 |
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- CEO
- W. Marc Hertz
- Employees
- 3
- Beta
- -1.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.18) − 1 = — (DCF, example).